HexemBio Raises $10.4 Million in Seed Funding
Biotechnology startup HexemBio has successfully raised $10.4 million in a seed funding round. This financial boost was led by Draper Associates, with additional participation from Seraphim and SOSV. The funding, announced on April 7, 2026, marks a significant step forward for the company as it aims to advance its innovative solutions in the biotech sector.
Leadership Team
HexemBio was co-founded by a team of experts with diverse backgrounds in biotechnology and business. The leadership team includes Gabriel Tremblay, who serves as the CEO, Mo Ebrahimkhani as the Chief Scientific Officer, Samet Yildirim as the Chief Business Officer, and Samira Kiani as the Chief Technology Officer. Each co-founder brings a wealth of experience to the table, driving the company’s mission to innovate within the biotech industry.
Use of Funds
While specific details on the allocation of the newly acquired funds were not disclosed, seed funding typically supports product development, research, and scaling operations. HexemBio is expected to use the resources to enhance its biotechnology offerings and possibly expand its team and infrastructure to accelerate growth.
Investors and Market Impact
The involvement of Draper Associates as the lead investor underscores the confidence in HexemBio’s potential. Draper Associates is known for backing early-stage ventures with transformative capabilities. Seraphim and SOSV, both reputable investors in the tech and biotech spaces, further bolster the company’s position in the market.
This seed round positions HexemBio for continued innovation and growth, as it works to bring new solutions to the biotech industry. The company's progress will be closely watched by industry stakeholders and investors alike as it moves forward with its plans.